Ascendis Pharma (ASND)
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
CAN FITE BIO (CANF)
Breakthrough Study from UCLA Demonstrate Can-Fite’sPiclidenoson as a Treatment for Vascular Dementia
COMPUGEN (CGEN)
Compugen - Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
InMed Pharmaceuticals Inc (INM)
InMed to Present INM-901 Data at Alzheimer’s Association International Conference (AAIC) 2025
Syndax Pharmaceuticals Inc (SNDX)
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Announces Private Placement Financing
Eton Pharmaceuticals Inc. (ETON)
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
COMPUGEN (CGEN)
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
CervoMed Inc (CRVO)
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
GSK plc (GLAXF)
Revvity Inc. (RVTY)
Revvity - Revvity Announces Financial Results for the Second Quarter of 2025
Serina Therapeutics, Inc. (SER)
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Revvity Inc. (RVTY)
Revvity Announces Financial Results for the Second Quarter of 2025
Zevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C